We present patient responses to ALK inhibitor-based targeted therapy with uterine IMT harboring <i>ALK-IGFBP5</i> fusion, and the neutrophil-to-lymphocyte ratio (NLR) may be an effective indicator to predict prognosis. Here, ALK is linked to inflammatory myofibroblastic tumor.